Evidence map›Paper›PMID 42369489›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Anti-Platelet Factor 4 Antibody Clonal Heterogeneity and MGUS Status in HIT.

Adam J Kanack, Emily E Mauch, Mindy C Kohlhagen, Jonathan Coker, David L Murray, Anand Padmanabhan

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Adam J KanackDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.
Emily E MauchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Mindy C KohlhagenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Jonathan CokerDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
David L MurrayDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Anand PadmanabhanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.

Funding

New approaches to the pathophysiology, diagnosis and management of heparin-induced thrombocytopeniaR01HL158932 · NHLBI · MAYO CLINIC ROCHESTER · PI PADMANABHAN, ANAND · 2021 to 2025
$2.0M
The role of proteoglycans in Heparin-induced thrombocytopenia: Implications for pathophysiology, diagnosis and treatmentK99HL171911 · NHLBI · MAYO CLINIC ROCHESTER · PI KANACK, ADAM J · 2024 to 2025
$332k
Determinants of Pathogenic Anti-PF4 Antibody-Mediated Platelet Activationathophysiology, diagnosis and treatmentR00HL171911 · NHLBI · MAYO CLINIC ARIZONA · PI Adam J Kanack · 2026 to 2026
$249k
NHLBI NIH HHS K99 HL171911NHLBI NIH HHS R00 HL171911NHLBI NIH HHS R01 HL158932
6 · The paper itself

Abstract

Background: Monoclonal gammopathy of thrombotic significance (MGTS) is a recently described chronic prothrombotic condition characterized by monoclonal anti-PF4 antibodies that are detected above the polyclonal antibody background in patient sera (i.e. present as monoclonal gammopathy of undetermined significance, MGUS). Due to conflicting data in the published literature on antibody clonality in heparin-induced thrombocytopenia (HIT), we evaluated clonality and abundance of anti-PF4 antibodies in HIT, including investigating whether an MGUS, if present in HIT, represents the causative anti-PF4 antibody. Methods: Blood samples from 15 patients with HIT were subject to Platelet Factor 4-dependent antigen-based and functional tests. The unmanipulated serum antibody repertoire and isolated anti-PF4 antibodies were subjected to mass spectrometric evaluation. Results: Two of the 15 HIT patients had an IgG MGUS. Notably, anti-PF4 antibodies were not synonymous with the MGUS antibody in either of the two patients. Eight of the 15 patients demonstrated monoclonal anti-PF4 antibodies, however, none of the anti-PF4 antibodies were detectable as an MGUS upon evaluation of the entire serum antibody repertoire, reflecting their low abundance. In the seven patients with multiple anti-PF4 antibodies, non-monoclonality was confirmed by analysis of deglycosylated antibody heavy chains. Conclusions: Anti-PF4 HIT antibodies are monoclonal in approximately 50% of HIT patients, however, antibody abundance is low such that they are not detectable over the polyclonal IgG background (i.e. are MGUS-negative), differentiating HIT from MGTS. This observation helps explain the transient nature of HIT relative to the persistent prothrombotic state seen in MGTS.

Identifiers

PMID42369489
PMCPMC13308072

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.